AGÕæÈ˹ٷ½

STOCK TITAN

[Form 4] Viridian Therapeutics, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Form 4 filing overview: Clover Health Investments (CLOV) reported insider activity by Jamie L. Reynoso, listed as “CEO, Medicare Advantage.� On 30 June 2025 Ms. Reynoso earned 217,523 Class A shares through the final tranche of a March 16 2023 performance-based RSU award. To satisfy withholding taxes, the company automatically sold 85,596 shares at $2.79 per share. After the automatic sale, Ms. Reynoso’s direct ownership stands at 3,328,328 Class A shares, up roughly 132 k shares versus the prior balance.

  • Nature of transaction: “Aâ€� code denotes acquisition from equity award; “Fâ€� code denotes shares withheld for taxes—neither represents an open-market trade.
  • Cost basis: RSUs were settled at no cash cost to the insider; only the tax-withholding sale carries a market price.
  • Alignment impact: The executive retains a sizable equity stake (â‰�3.3 million shares), reinforcing incentive alignment, but no new cash investment was made.

Overall, the filing reflects routine equity-compensation vesting and related tax withholding rather than a discretionary buy or sell decision. Market impact is expected to be neutral barring other catalysts.

Panoramica della segnalazione Form 4: Clover Health Investments (CLOV) ha riportato un'attività interna da parte di Jamie L. Reynoso, indicata come “CEO, Medicare Advantage.� Il 30 giugno 2025 la signora Reynoso ha acquisito 217.523 azioni di Classe A tramite la tranche finale di un premio RSU basato sulle performance del 16 marzo 2023. Per coprire le imposte da trattenere, la società ha venduto automaticamente 85.596 azioni a 2,79$ ciascuna. Dopo questa vendita automatica, la proprietà diretta della signora Reynoso ammonta a 3.328.328 azioni di Classe A, con un incremento di circa 132.000 azioni rispetto al saldo precedente.

  • Natura della transazione: Il codice “Aâ€� indica l’acquisizione da premio azionario; il codice “Fâ€� indica azioni trattenute per tasse—nessuno dei due rappresenta un’operazione sul mercato aperto.
  • Base di costo: Le RSU sono state assegnate senza alcun costo in denaro per l’insider; solo la vendita per ritenuta fiscale ha un prezzo di mercato.
  • Impatto sull’allineamento: L’esecutivo mantiene una consistente partecipazione azionaria (circa 3,3 milioni di azioni), rafforzando l’allineamento degli incentivi, ma non è stato effettuato alcun nuovo investimento in contanti.

In generale, la segnalazione riflette una normale maturazione di compensi azionari e relative trattenute fiscali, piuttosto che una decisione discrezionale di acquisto o vendita. L’impatto sul mercato è previsto neutrale salvo altri eventi.

Resumen de la presentación del Formulario 4: Clover Health Investments (CLOV) reportó actividad interna por parte de Jamie L. Reynoso, designada como “CEO, Medicare Advantage.� El 30 de junio de 2025, la Sra. Reynoso obtuvo 217,523 acciones Clase A mediante el tramo final de una concesión de RSU basada en desempeño del 16 de marzo de 2023. Para cubrir impuestos retenidos, la compañía vendió automáticamente 85,596 acciones a $2.79 por acción. Tras esta venta automática, la propiedad directa de la Sra. Reynoso es de 3,328,328 acciones Clase A, un aumento de aproximadamente 132,000 acciones respecto al saldo anterior.

  • Naturaleza de la transacción: El código “Aâ€� indica adquisición por premio de capital; el código “Fâ€� indica acciones retenidas para impuestos—ninguno representa una operación en mercado abierto.
  • Base de costo: Las RSU se liquidaron sin costo en efectivo para el insider; solo la venta por retención fiscal tiene precio de mercado.
  • Impacto en la alineación: La ejecutiva mantiene una participación significativa (â‰�3.3 millones de acciones), reforzando la alineación de incentivos, pero no realizó nueva inversión en efectivo.

En general, la presentación refleja la consolidación rutinaria de compensación en acciones y la retención fiscal correspondiente, más que una decisión discrecional de compra o venta. Se espera un impacto neutral en el mercado salvo otros catalizadores.

Form 4 제출 개요: Clover Health Investments (CLOV)ëŠ� “CEO, Medicare Advantageâ€ë¡œ 등재ë� Jamie L. Reynosoì� ë‚´ë¶€ìž� 활ë™ì� 보고했습니다. 2025ë…� 6ì›� 30ì�, Reynoso 씨는 2023ë…� 3ì›� 16ì� 성과 기반 RSU 수여ì� 마지ë§� ë¶„í• ë¡� 217,523ì£� í´ëž˜ìŠ� A 주ì‹ì� ì·¨ë“했습니다. ì›ì²œì§•수 세금ì� 충당하기 위해 회사ëŠ� ìžë™ìœ¼ë¡œ 85,596주를 주당 2.79달러ì—� 매ë„했습니다. ìžë™ ë§¤ë„ í›� Reynoso ì”¨ì˜ ì§ì ‘ 소유 주ì‹ì€ 3,328,328ì£� í´ëž˜ìŠ� A 주ì‹ìœ¼ë¡œ, ì´ì „ 잔고 대ë¹� ì•� 13ë§� 2ì²� ì£� ì¦ê°€í–ˆìŠµë‹ˆë‹¤.

  • 거래 성격: “Aâ€� 코드ëŠ� ì£¼ì‹ ë³´ìƒì—서ì� ì·¨ë“ì�, “Fâ€� 코드ëŠ� 세금 ì›ì²œì§•수ë¥� 위한 ì£¼ì‹ ë³´ìœ ë¥� 나타내며, ë‘� ë‹� 공개 시장 거래ë¥� ì˜ë¯¸í•˜ì§€ 않습니다.
  • ì›ê°€ 기준: RSUëŠ� ë‚´ë¶€ìžì—ê²� 현금 비용 ì—†ì´ ì •ì‚°ë˜ì—ˆìœ¼ë©°, 세금 ì›ì²œì§•수 매ë„ë§� 시장 ê°€ê²©ì´ ì ìš©ë©ë‹ˆë‹�.
  • ì •ë ¬ ì˜í–¥: ìž„ì›ì€ ìƒë‹¹í•� ì§€ë¶�(ì•� 330ë§� ì£�)ì� 유지하여 ì¸ì„¼í‹°ë¸Œ ì •ë ¬ì� 강화했으ë‚�, 새로ìš� 현금 투ìžëŠ� ì´ë£¨ì–´ì§€ì§€ 않았습니ë‹�.

ì „ë°˜ì ìœ¼ë¡� ì´ë²ˆ ì œì¶œì€ ìž„ì§ì›� ì£¼ì‹ ë³´ìƒ ë§Œê¸° ë°� ê´€ë � 세금 ì›ì²œì§•수ë¥� ë°˜ì˜í•� 것으ë¡�, ìž„ì˜ì� 매매 ê²°ì •ì� 아닙니다. 다른 촉매가 없는 í•� 시장 ì˜í–¥ì€ 중립ì �ì� 것으ë¡� 예ìƒë©ë‹ˆë‹�.

Résumé du dépôt du Formulaire 4 : Clover Health Investments (CLOV) a signalé une activité d’initié par Jamie L. Reynoso, désignée comme « CEO, Medicare Advantage ». Le 30 juin 2025, Mme Reynoso a acquis 217 523 actions de classe A via la tranche finale d’une attribution de RSU basée sur la performance datant du 16 mars 2023. Pour couvrir les retenues fiscales, la société a automatiquement vendu 85 596 actions à 2,79 $ chacune. Après cette vente automatique, la détention directe de Mme Reynoso s’élève à 3 328 328 actions de classe A, soit une augmentation d’environ 132 000 actions par rapport au solde précédent.

  • Nature de la transaction : Le code « A » désigne une acquisition via attribution d’actions ; le code « F » désigne les actions retenues pour impôts â€� aucune n’est une opération sur le marché ouvert.
  • Base de coût : Les RSU ont été réglées sans coût en numéraire pour l’initié ; seule la vente liée à la retenue fiscale a un prix de marché.
  • Impact sur l’alignement : La dirigeante conserve une participation importante (â‰� 3,3 millions d’actions), renforçant l’alignement des incitations, sans nouvel investissement en numéraire.

Globalement, le dépôt reflète un dénouement habituel de rémunération en actions et la retenue fiscale associée, plutôt qu’une décision discrétionnaire d’achat ou de vente. L’impact sur le marché est attendu neutre, sauf autres catalyseurs.

Übersicht der Form 4 Meldung: Clover Health Investments (CLOV) meldete Insideraktivitäten von Jamie L. Reynoso, angegeben als „CEO, Medicare Advantage�. Am 30. Juni 2025 erhielt Frau Reynoso 217.523 Class-A-Aktien durch die letzte Tranche einer leistungsabhängigen RSU-Zuteilung vom 16. März 2023. Zur Begleichung der Quellensteuer verkaufte das Unternehmen automatisch 85.596 Aktien zu je 2,79 $. Nach dem automatischen Verkauf hält Frau Reynoso direkt 3.328.328 Class-A-Aktien, was einem Anstieg von etwa 132.000 Aktien gegenüber dem vorherigen Bestand entspricht.

  • Art der Transaktion: Der Code „Aâ€� steht für Erwerb durch Aktienzuteilung; der Code „Fâ€� für einbehaltene Aktien zur Steuerzahlung â€� beides sind keine offenen Markttransaktionen.
  • Kostenbasis: Die RSUs wurden ohne Barausgabe für den Insider abgewickelt; nur der Verkauf zur Steuerabführung erfolgte zum Marktpreis.
  • Auswirkung auf die Ausrichtung: Die Führungskraft hält weiterhin eine bedeutende Beteiligung (ca. 3,3 Millionen Aktien), was die Anreizausrichtung stärkt, jedoch wurde keine neue Barinvestition getätigt.

Insgesamt spiegelt die Meldung eine routinemäßige Ausübung von aktienbasierter Vergütung und die damit verbundene Steuerabführung wider, keine bewusste Kauf- oder Verkaufsentscheidung. Die Marktauswirkung wird neutral erwartet, sofern keine weiteren Ereignisse eintreten.

Positive
  • Executive ownership rises by ~132,000 shares, increasing alignment with shareholders.
  • Performance-based vesting suggests the company met or exceeded predefined targets tied to the 2023 RSU grant.
Negative
  • None.

Insights

TL;DR: Routine RSU vesting—neutral impact; insider’s stake increases, no open-market buying.

The 217.5 k share addition arises from a scheduled performance-based RSU vesting. The automatic 85.6 k-share sale merely covers payroll taxes. Net beneficial ownership growth of ~132 k shares (�4 % of her prior holdings) is not large enough to signal a strong incremental vote of confidence, but it modestly enhances alignment. Because there is no discretionary purchase or sale, I view the filing as informational, not directional. Trading volume impact should be minimal.

TL;DR: Performance-based vesting confirms compensation plan progression; governance concerns minimal.

The disclosure shows Clover Health’s incentive structure functioning as designed: shares vest only after performance hurdles, with automatic tax withholding to avoid insider liquidity strain. The executive’s continued sizable ownership (3.3 M shares) exceeds common ownership guidelines, fostering shareholder alignment. There are no indications of problematic timing, 10b5-1 usage, or unusual dispositions. Therefore, the governance signal is neutral-to-slightly-positive, but not materially impactful to valuation.

Panoramica della segnalazione Form 4: Clover Health Investments (CLOV) ha riportato un'attività interna da parte di Jamie L. Reynoso, indicata come “CEO, Medicare Advantage.� Il 30 giugno 2025 la signora Reynoso ha acquisito 217.523 azioni di Classe A tramite la tranche finale di un premio RSU basato sulle performance del 16 marzo 2023. Per coprire le imposte da trattenere, la società ha venduto automaticamente 85.596 azioni a 2,79$ ciascuna. Dopo questa vendita automatica, la proprietà diretta della signora Reynoso ammonta a 3.328.328 azioni di Classe A, con un incremento di circa 132.000 azioni rispetto al saldo precedente.

  • Natura della transazione: Il codice “Aâ€� indica l’acquisizione da premio azionario; il codice “Fâ€� indica azioni trattenute per tasse—nessuno dei due rappresenta un’operazione sul mercato aperto.
  • Base di costo: Le RSU sono state assegnate senza alcun costo in denaro per l’insider; solo la vendita per ritenuta fiscale ha un prezzo di mercato.
  • Impatto sull’allineamento: L’esecutivo mantiene una consistente partecipazione azionaria (circa 3,3 milioni di azioni), rafforzando l’allineamento degli incentivi, ma non è stato effettuato alcun nuovo investimento in contanti.

In generale, la segnalazione riflette una normale maturazione di compensi azionari e relative trattenute fiscali, piuttosto che una decisione discrezionale di acquisto o vendita. L’impatto sul mercato è previsto neutrale salvo altri eventi.

Resumen de la presentación del Formulario 4: Clover Health Investments (CLOV) reportó actividad interna por parte de Jamie L. Reynoso, designada como “CEO, Medicare Advantage.� El 30 de junio de 2025, la Sra. Reynoso obtuvo 217,523 acciones Clase A mediante el tramo final de una concesión de RSU basada en desempeño del 16 de marzo de 2023. Para cubrir impuestos retenidos, la compañía vendió automáticamente 85,596 acciones a $2.79 por acción. Tras esta venta automática, la propiedad directa de la Sra. Reynoso es de 3,328,328 acciones Clase A, un aumento de aproximadamente 132,000 acciones respecto al saldo anterior.

  • Naturaleza de la transacción: El código “Aâ€� indica adquisición por premio de capital; el código “Fâ€� indica acciones retenidas para impuestos—ninguno representa una operación en mercado abierto.
  • Base de costo: Las RSU se liquidaron sin costo en efectivo para el insider; solo la venta por retención fiscal tiene precio de mercado.
  • Impacto en la alineación: La ejecutiva mantiene una participación significativa (â‰�3.3 millones de acciones), reforzando la alineación de incentivos, pero no realizó nueva inversión en efectivo.

En general, la presentación refleja la consolidación rutinaria de compensación en acciones y la retención fiscal correspondiente, más que una decisión discrecional de compra o venta. Se espera un impacto neutral en el mercado salvo otros catalizadores.

Form 4 제출 개요: Clover Health Investments (CLOV)ëŠ� “CEO, Medicare Advantageâ€ë¡œ 등재ë� Jamie L. Reynosoì� ë‚´ë¶€ìž� 활ë™ì� 보고했습니다. 2025ë…� 6ì›� 30ì�, Reynoso 씨는 2023ë…� 3ì›� 16ì� 성과 기반 RSU 수여ì� 마지ë§� ë¶„í• ë¡� 217,523ì£� í´ëž˜ìŠ� A 주ì‹ì� ì·¨ë“했습니다. ì›ì²œì§•수 세금ì� 충당하기 위해 회사ëŠ� ìžë™ìœ¼ë¡œ 85,596주를 주당 2.79달러ì—� 매ë„했습니다. ìžë™ ë§¤ë„ í›� Reynoso ì”¨ì˜ ì§ì ‘ 소유 주ì‹ì€ 3,328,328ì£� í´ëž˜ìŠ� A 주ì‹ìœ¼ë¡œ, ì´ì „ 잔고 대ë¹� ì•� 13ë§� 2ì²� ì£� ì¦ê°€í–ˆìŠµë‹ˆë‹¤.

  • 거래 성격: “Aâ€� 코드ëŠ� ì£¼ì‹ ë³´ìƒì—서ì� ì·¨ë“ì�, “Fâ€� 코드ëŠ� 세금 ì›ì²œì§•수ë¥� 위한 ì£¼ì‹ ë³´ìœ ë¥� 나타내며, ë‘� ë‹� 공개 시장 거래ë¥� ì˜ë¯¸í•˜ì§€ 않습니다.
  • ì›ê°€ 기준: RSUëŠ� ë‚´ë¶€ìžì—ê²� 현금 비용 ì—†ì´ ì •ì‚°ë˜ì—ˆìœ¼ë©°, 세금 ì›ì²œì§•수 매ë„ë§� 시장 ê°€ê²©ì´ ì ìš©ë©ë‹ˆë‹�.
  • ì •ë ¬ ì˜í–¥: ìž„ì›ì€ ìƒë‹¹í•� ì§€ë¶�(ì•� 330ë§� ì£�)ì� 유지하여 ì¸ì„¼í‹°ë¸Œ ì •ë ¬ì� 강화했으ë‚�, 새로ìš� 현금 투ìžëŠ� ì´ë£¨ì–´ì§€ì§€ 않았습니ë‹�.

ì „ë°˜ì ìœ¼ë¡� ì´ë²ˆ ì œì¶œì€ ìž„ì§ì›� ì£¼ì‹ ë³´ìƒ ë§Œê¸° ë°� ê´€ë � 세금 ì›ì²œì§•수ë¥� ë°˜ì˜í•� 것으ë¡�, ìž„ì˜ì� 매매 ê²°ì •ì� 아닙니다. 다른 촉매가 없는 í•� 시장 ì˜í–¥ì€ 중립ì �ì� 것으ë¡� 예ìƒë©ë‹ˆë‹�.

Résumé du dépôt du Formulaire 4 : Clover Health Investments (CLOV) a signalé une activité d’initié par Jamie L. Reynoso, désignée comme « CEO, Medicare Advantage ». Le 30 juin 2025, Mme Reynoso a acquis 217 523 actions de classe A via la tranche finale d’une attribution de RSU basée sur la performance datant du 16 mars 2023. Pour couvrir les retenues fiscales, la société a automatiquement vendu 85 596 actions à 2,79 $ chacune. Après cette vente automatique, la détention directe de Mme Reynoso s’élève à 3 328 328 actions de classe A, soit une augmentation d’environ 132 000 actions par rapport au solde précédent.

  • Nature de la transaction : Le code « A » désigne une acquisition via attribution d’actions ; le code « F » désigne les actions retenues pour impôts â€� aucune n’est une opération sur le marché ouvert.
  • Base de coût : Les RSU ont été réglées sans coût en numéraire pour l’initié ; seule la vente liée à la retenue fiscale a un prix de marché.
  • Impact sur l’alignement : La dirigeante conserve une participation importante (â‰� 3,3 millions d’actions), renforçant l’alignement des incitations, sans nouvel investissement en numéraire.

Globalement, le dépôt reflète un dénouement habituel de rémunération en actions et la retenue fiscale associée, plutôt qu’une décision discrétionnaire d’achat ou de vente. L’impact sur le marché est attendu neutre, sauf autres catalyseurs.

Übersicht der Form 4 Meldung: Clover Health Investments (CLOV) meldete Insideraktivitäten von Jamie L. Reynoso, angegeben als „CEO, Medicare Advantage�. Am 30. Juni 2025 erhielt Frau Reynoso 217.523 Class-A-Aktien durch die letzte Tranche einer leistungsabhängigen RSU-Zuteilung vom 16. März 2023. Zur Begleichung der Quellensteuer verkaufte das Unternehmen automatisch 85.596 Aktien zu je 2,79 $. Nach dem automatischen Verkauf hält Frau Reynoso direkt 3.328.328 Class-A-Aktien, was einem Anstieg von etwa 132.000 Aktien gegenüber dem vorherigen Bestand entspricht.

  • Art der Transaktion: Der Code „Aâ€� steht für Erwerb durch Aktienzuteilung; der Code „Fâ€� für einbehaltene Aktien zur Steuerzahlung â€� beides sind keine offenen Markttransaktionen.
  • Kostenbasis: Die RSUs wurden ohne Barausgabe für den Insider abgewickelt; nur der Verkauf zur Steuerabführung erfolgte zum Marktpreis.
  • Auswirkung auf die Ausrichtung: Die Führungskraft hält weiterhin eine bedeutende Beteiligung (ca. 3,3 Millionen Aktien), was die Anreizausrichtung stärkt, jedoch wurde keine neue Barinvestition getätigt.

Insgesamt spiegelt die Meldung eine routinemäßige Ausübung von aktienbasierter Vergütung und die damit verbundene Steuerabführung wider, keine bewusste Kauf- oder Verkaufsentscheidung. Die Marktauswirkung wird neutral erwartet, sofern keine weiteren Ereignisse eintreten.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
CAIN CHRISTOPHER W.

(Last) (First) (Middle)
C/O VIRIDIAN THERAPEUTICS, INC.
221 CRESCENT STREET, SUITE 103A

(Street)
WALTHAM MA 02453

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Viridian Therapeutics, Inc.\DE [ VRDN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
07/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $14.47 07/01/2025 A 21,000 (1) 07/01/2035 Common Stock 21,000 $0.00 21,000 I See Footnote(2)
Explanation of Responses:
1. The option vests in full upon the earlier to occur of (i) July 1, 2026 or (ii) the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer.
2. Under the Reporting Person's arrangement with Fairmount Funds Management LLC (the "Adviser"), the Reporting Person holds the option for one or more investment vehicles managed by the Adviser (each, a "Fairmount Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.
/s/ Jennifer Tousignant, Attorney-in-fact 07/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Jamie L. Reynoso report for CLOV?

217,523 RSUs vested and 85,596 shares were withheld for taxes on 30 June 2025.

How many Clover Health shares does Reynoso own after the Form 4 filing?

She now directly owns 3,328,328 Class A shares.

Were any open-market purchases or sales involved?

No. The acquisition came from RSU vesting; the share sale was automatic tax withholding, not discretionary trading.

At what price were shares sold to cover taxes?

Shares were sold at $2.79 per share.

Does the filing indicate use of a Rule 10b5-1 plan?

No Rule 10b5-1 box is marked; the sale was automatic for tax withholding.
Viridian Therapeutics Inc

NASDAQ:VRDN

VRDN Rankings

VRDN Latest News

VRDN Latest SEC Filings

VRDN Stock Data

1.19B
80.80M
0.12%
114.02%
11.74%
Biotechnology
Services-medical Laboratories
United States
WALTHAM